PepCalcs
    Back to Library

    Tesofensine

    Research Use OnlyInvestigational New Drug (US)

    Tesofensine

    Description

    A serotonin-norepinephrine-dopamine reuptake inhibitor originally studied as an anti-obesity agent. Promotes weight loss through appetite suppression.

    Dose:0.25-1 mg
    Frequency:Daily
    Administration Method: Oral
    CategoryWeight Loss
    Half-Life~220 hours

    Overview

    Tesofensine was originally studied for neurodegenerative disease and was found to induce weight loss by reducing hunger and increasing satiety, shifting the focus toward obesity treatment.

    Mechanism of Action

    Tesofensine is a triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine - SNDRI) that modulates appetite, energy expenditure, and motivation.

    Benefits

    • •Weight loss
    • •Appetite suppression
    • •Metabolic enhancement
    • •Energy increase
    • •Fat burning

    Dosing Notes

    Most weight-loss trials evaluated oral doses of 0.25, 0.5, and 1 mg/day. 0.5 mg/day showed the most balanced efficacy/tolerability; 1 mg/day produced more weight loss but more side effects.

    Reported Side Effects

    • •dry mouth
    • •constipation
    • •insomnia
    • •increased heart rate
    • •mild changes in blood pressure

    Safety Notes

    Side effects increase with dose. Because tesofensine has a very long half-life, adverse effects may persist if the dose is too high.

    Scientific References

    PubChem (NIH)Wikipedia

    Related Weight Loss Peptides

    AOD-9604

    Anti-Obesity Drug 9604

    A synthetic peptide analog of natural AOD-9604 fragment that stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 or insulin.

    300 mcg

    5-Amino-1MQ

    5-Amino-1-Methylquinolinium

    A small molecule that inhibits NNMT enzyme, boosting NAD+ levels and cellular energy. Supports fat loss and metabolic function.

    1 mg

    Ipamorelin/CJC-1295 No DAC

    Ipamorelin and CJC-1295 without DAC Blend

    A powerful synergistic combination of growth hormone secretagogues. Ipamorelin provides selective GH release while CJC-1295 extends GH pulse duration for enhanced fat loss and recovery.

    250 mcg each

    Triple Threat Blend

    NAD+, MOTS-c, and 5-Amino-1MQ Blend

    A synergistic combination targeting mitochondrial function, cellular energy, and fat metabolism. Combines NAD+ precursor with mitochondrial peptide and NNMT inhibitor for comprehensive metabolic support.

    10 mg/1mg/1mg